Milind Javle, MD, The University of Texas MD Anderson Cancer Center
Articles by Milind Javle, MD, The University of Texas MD Anderson Cancer Center
Advanced BTC: Informing Use of IO Therapy in Specific Patient Populations
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Aiwu Ruth He, MD, PhD,Anjana Pillai, MD,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University,Mark Yarchoan, MD Shared insight on efforts to identify patient subgroups that may benefit more from immunotherapy in the setting of advanced biliary tract cancers.
TOPAZ-1: Durvalumab + Doublet Chemotherapy in Advanced Biliary Tract Cancers
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Aiwu Ruth He, MD, PhD,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University,Mark Yarchoan, MD Centering their conversation on the TOPAZ-1 clinical trial, expert panelists review the use of IO + chemotherapy in advanced biliary tract cancers.
Advanced Biliary Tract Cancers: First- and Second-Line Chemotherapy
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Aiwu Ruth He, MD, PhD,Anjana Pillai, MD,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University,Mark Yarchoan, MD Focused discussion on chemotherapy treatment options commonplace in patients with advanced or metastatic biliary tract cancers.
An Overview of Systemic Therapy for Advanced Biliary Tract Cancers
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Aiwu Ruth He, MD, PhD,Anjana Pillai, MD,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University,Mark Yarchoan, MD Shifting their focus to the advanced disease setting, panelists provide a comprehensive overview on systemic treatment modalities used in biliary tract cancers.
Understanding the Role of Adjuvant Therapy in Biliary Tract Cancers
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Aiwu Ruth He, MD, PhD,Anjana Pillai, MD,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University,Mark Yarchoan, MD Experts provide brief perspective on the use of adjuvant treatment approaches for patients with biliary tract cancers.
What is the Role of Transplant in Early-Stage Biliary Tract Cancers?
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Aiwu Ruth He, MD, PhD,Anjana Pillai, MD,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University,Mark Yarchoan, MD Before closing out their review of early-stage biliary tract cancer treatment options, panelists consider the role of transplant in the setting.
Treatment Options for Early-Stage Biliary Tract Cancers
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Aiwu Ruth He, MD, PhD,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University,Mark Yarchoan, MD Centering discussion on early-stage biliary tract cancers, expert panelists consider the respective roles of surgery and embolization strategies in this setting.
Guidelines for Molecular Testing in Biliary Tract Cancers
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Aiwu Ruth He, MD, PhD,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University,Mark Yarchoan, MD Panelists share their perspectives on molecular testing guidelines for patients diagnosed with biliary tract cancers.
Biliary Tract Cancers: Staging and Clinicopathologic Features
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Aiwu Ruth He, MD, PhD,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University,Mark Yarchoan, MD Comprehensive insight on staging biliary tract cancers followed by an overview of molecular testing and targetable clinicopathologic features.
Challenges in Diagnosing Biliary Tract Cancers
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Aiwu Ruth He, MD, PhD,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University,Mark Yarchoan, MD Expert perspectives on the presentation of biliary tract cancers with specific insight to the challenges inherent in reaching a timely diagnosis.
Incidence and Risk Factors for Biliary Tract Cancers
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Aiwu Ruth He, MD, PhD,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University,Mark Yarchoan, MD Shared insight on the global incidence of biliary tract cancers and which risk factors most impact the likelihood of disease.
An Overview on Biliary Tract Cancers
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Aiwu Ruth He, MD, PhD,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Mark Yarchoan, MD,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University Opening their discussion on biliary tract cancers, a multidisciplinary panel of experts consider how specific subsets of these malignancies differ from one another.
OncLive sits down with Erika P. Hamilton, MD, and Milind Javle, MD, on the pivotal studies in breast cancer and gastrointestinal cancers, respectively, at the 2021 ASCO Annual Meeting.
Milind Javle, MD, discusses the FDA approval of infigratinib in FGFR-mutated cholangiocarcinoma.
Perspectives on Treating CCA Moving Forward
ByJohn L. Marshall, MD, The Ruesch Center for the Cure of GI Cancers,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center A panel of GI oncologists share their thoughts on the future of using precision medicine to treat patients with bile duct cancers.
Immunotherapy for Advanced Cholangiocarcinoma
ByJohn L. Marshall, MD, The Ruesch Center for the Cure of GI Cancers,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center The role of MSI testing and potential use of immunotherapy to treat patients with advanced cholangiocarcinoma.
Cholangiocarcinoma: Potential Therapies Under Investigation
ByJohn L. Marshall, MD, The Ruesch Center for the Cure of GI Cancers,R. Kate Kelley, MD, University of California-San Francisco,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center An overview of various treatment opportunities under study that are looking at using novel techniques to help personalize treatment for patients with bile duct cancers.
IDH Targeting in Advanced Cholangiocarcinoma
ByJohn L. Marshall, MD, The Ruesch Center for the Cure of GI Cancers,R. Kate Kelley, MD, University of California-San Francisco,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center Considerations for treating appropriate patients with advanced cholangiocarcinoma with an IDH inhibitor.
Implications for Using FGFR Inhibitors in Advanced CCA
ByJohn L. Marshall, MD, The Ruesch Center for the Cure of GI Cancers,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center Milind Javle, MD, of The University of Texas MD Anderson Cancer Center, explains what GI oncologists can expect from FGFR treatment for advanced cholangiocarcinoma in terms of treatment responses.
FGFR Inhibitors for Advanced Cholangiocarcinoma: Adverse Events
ByJohn L. Marshall, MD, The Ruesch Center for the Cure of GI Cancers,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center Recommendations for appropriately managing patients who experience adverse events associated with FGFR treatment for advanced cholangiocarcinoma.
FGFR Inhibitors for Advanced Cholangiocarcinoma
ByJohn L. Marshall, MD, The Ruesch Center for the Cure of GI Cancers,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center R. Kate Kelley, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, comments on the rationale for treating patients with advanced cholangiocarcinoma with an FGFR inhibitor.
Promoting the Importance of Molecular Testing in CCA
ByJohn L. Marshall, MD, The Ruesch Center for the Cure of GI Cancers,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center The value of early molecular testing in cholangiocarcinoma and importance of promoting its role to both patients and GI oncologists.
Advanced Cholangiocarcinoma: Molecular Testing
ByJohn L. Marshall, MD, Georgetown University,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center Experts who treat patients with GI cancers, such as cholangiocarcinoma, emphasize the need for more standardized approaches to molecular testing.
Advanced Cholangiocarcinoma: Transition to Precision Medicine
ByJohn L. Marshall, MD, Georgetown University,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center A panel of GI oncologists comment on the transition to targeted therapy and immunotherapy as treatments for advanced cholangiocarcinoma, as well as highlight predictive and prognostic markers that can help guide treatment decisions with novel therapies.
Treating Unresectable, Advanced Cholangiocarcinoma
ByJohn L. Marshall, MD, Georgetown University,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center Treatment recommendations, including supportive care options and the role of liver-directed therapy for patients with an unresectable, advanced bile duct cancer.
Neoadjuvant Therapy for Advanced Cholangiocarcinoma
ByJohn L. Marshall, MD, Georgetown University,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center An overview of potential options, as well as trials, further exploring neoadjuvant approaches for the management of patients with advanced cholangiocarcinoma.
Optimizing Adjuvant Therapy for Advanced Cholangiocarcinoma
ByJohn L. Marshall, MD, Georgetown University,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center Insight regarding best timing to initiate an appropriate adjuvant therapy in patients with advanced cholangiocarcinoma, and the role of ctDNA analysis in the postsurgical setting.
Adjuvant Therapy for Advanced Cholangiocarcinoma
ByJohn L. Marshall, MD, Georgetown University,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center Current treatment approaches for advanced cholangiocarcinoma, despite current gaps that can be considered in the adjuvant setting, as highlighted by GI oncologists.
Liver Transplantation for Advanced Cholangiocarcinoma
ByJohn L. Marshall, MD, Georgetown University,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center Scenarios for which liver transplantation may be appropriate in advanced cholangiocarcinoma.
Advanced Cholangiocarcinoma: Criteria for Resection
ByJohn L. Marshall, MD, Georgetown University,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center Panelists discuss types of scans and other testing results that can be used to help identify patients with an advanced bile duct cancer who are eligible for surgical resection.
